The University of Southampton
University of Southampton Institutional Repository

Cytokine and anti-cytokine therapy for the treatment of asthma and allergic disease

Cytokine and anti-cytokine therapy for the treatment of asthma and allergic disease
Cytokine and anti-cytokine therapy for the treatment of asthma and allergic disease
Until recently, the only controller treatment for chronic asthma has been corticosteroids. However, identification of specific effector molecules in asthma has led to targeting of specific pathways by using cytokines and cytokine inhibitors. Administration of a monoclonal blocking antibody against IgE has been shown to be highly efficacious in severe allergic asthma, but blockade of eosinophils using anti-IL-5 monoclonal antibodies has no clinical benefit. In more severe asthma, blockade of TNF-alpha using the decoy etanercept has revealed efficacy in a small open study suggesting that Th-1 in addition to Th-2 pathways are important as the disease adopts a more severe phenotype. It is likely that asthma is not a single disease but a group of disorders which differ in the relative contribution of specific pathophysiological pathways.
asthma, cytokines, anti-TNF-?, anti-IL-5, anti-IL-4
1043-4666
152-157
Holgate, Stephen T.
2e7c17a9-6796-436e-8772-1fe6d2ac5edc
Holgate, Stephen T.
2e7c17a9-6796-436e-8772-1fe6d2ac5edc

Holgate, Stephen T. (2004) Cytokine and anti-cytokine therapy for the treatment of asthma and allergic disease. Cytokine, 28 (4-5), 152-157. (doi:10.1016/j.cyto.2004.07.010).

Record type: Article

Abstract

Until recently, the only controller treatment for chronic asthma has been corticosteroids. However, identification of specific effector molecules in asthma has led to targeting of specific pathways by using cytokines and cytokine inhibitors. Administration of a monoclonal blocking antibody against IgE has been shown to be highly efficacious in severe allergic asthma, but blockade of eosinophils using anti-IL-5 monoclonal antibodies has no clinical benefit. In more severe asthma, blockade of TNF-alpha using the decoy etanercept has revealed efficacy in a small open study suggesting that Th-1 in addition to Th-2 pathways are important as the disease adopts a more severe phenotype. It is likely that asthma is not a single disease but a group of disorders which differ in the relative contribution of specific pathophysiological pathways.

This record has no associated files available for download.

More information

Published date: 2004
Keywords: asthma, cytokines, anti-TNF-?, anti-IL-5, anti-IL-4

Identifiers

Local EPrints ID: 27120
URI: http://eprints.soton.ac.uk/id/eprint/27120
ISSN: 1043-4666
PURE UUID: f704da17-8c1e-4de5-90e6-1ec5d4a94cc3

Catalogue record

Date deposited: 26 Apr 2006
Last modified: 15 Mar 2024 07:15

Export record

Altmetrics

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×